The Lebanon Healthcare Journal
SEE OTHER BRANDS

Fresh health and wellness news from Lebanon

The Lebanon Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Lebanon Healthcare Journal.

Press releases published on May 29, 2025

MDaudit and Streamline Health Announce Definitive Merger Agreement

MDaudit and Streamline Health Announce Definitive Merger Agreement

The combined entity supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B and brings together best-in-class billing compliance and revenue integrity solutions to empower health systems with actionable …

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, …

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …

Reflect Scientific Completes $550,000 Next-Generation Freezer Installation for Pharmaceutical Client

Reflect Scientific Completes $550,000 Next-Generation Freezer Installation for Pharmaceutical Client

OREM, Utah, May 29, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in ultra-low temperature freezer technology, today announced the successful completion of a major installation project valued at $550,000. The deployment, which …

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO to Present at Jefferies Global Healthcare Conference

ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …

Septerna to Present at Jefferies Global Healthcare Conference

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive …

Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of …

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its presentation at the …

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the …

New study shows significant decline in men’s mental health; half lack sufficient social support

New study shows significant decline in men’s mental health; half lack sufficient social support

Stress and depression risk increase for Canadian men One in two men lack sufficient social support networks Canadian Men’s Health Foundation launches #NeverAlone campaign for Men’s Health Month in June VANCOUVER, British Columbia, May 29, 2025 (GLOBE …

DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District

DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, is pleased to announce the strategic …

Erasca to Present at Upcoming Investor Conferences in June

Erasca to Present at Upcoming Investor Conferences in June

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE …

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient …

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment …

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at …

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical …

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service